Last reviewed · How we verify
Ramipril + Felodipine
Ramipril + Felodipine is a ACE inhibitor + calcium channel blocker combination Small molecule drug developed by Sanofi. It is currently FDA-approved for Hypertension.
This combination lowers blood pressure by blocking angiotensin II formation (ramipril) and relaxing blood vessel smooth muscle (felodipine).
This combination lowers blood pressure by blocking angiotensin II formation (ramipril) and relaxing blood vessel smooth muscle (felodipine). Used for Hypertension.
At a glance
| Generic name | Ramipril + Felodipine |
|---|---|
| Sponsor | Sanofi |
| Drug class | ACE inhibitor + calcium channel blocker combination |
| Target | Angiotensin-converting enzyme (ACE) and L-type voltage-gated calcium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ramipril is an ACE inhibitor that prevents conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Felodipine is a dihydropyridine calcium channel blocker that directly relaxes vascular smooth muscle by blocking L-type calcium channels. Together, they provide complementary antihypertensive effects with different mechanisms of action.
Approved indications
- Hypertension
Common side effects
- Cough
- Headache
- Dizziness
- Peripheral edema
- Fatigue
- Flushing
- Palpitations
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Coronavirus (COVID-19) ACEi/ARB Investigation (PHASE4)
- Efficacy and Safety of the Combination of Valsartan Plus Amlodipine in Hypertensive Patients Not Adequately Responding to the Combination Therapy With Ramipril Plus Felodipine (PHASE3)
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) (PHASE3)
- China Medical University Hospital (CMUH) Triapin Listing (PHASE4)
- Use of Ramipril and Felodipine Combination Therapy in Hypertension: An Effectiveness Study With Local Patients in Argentina (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ramipril + Felodipine CI brief — competitive landscape report
- Ramipril + Felodipine updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Ramipril + Felodipine
What is Ramipril + Felodipine?
How does Ramipril + Felodipine work?
What is Ramipril + Felodipine used for?
Who makes Ramipril + Felodipine?
What drug class is Ramipril + Felodipine in?
What development phase is Ramipril + Felodipine in?
What are the side effects of Ramipril + Felodipine?
What does Ramipril + Felodipine target?
Related
- Drug class: All ACE inhibitor + calcium channel blocker combination drugs
- Target: All drugs targeting Angiotensin-converting enzyme (ACE) and L-type voltage-gated calcium channels
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Compare: Ramipril + Felodipine vs similar drugs
- Pricing: Ramipril + Felodipine cost, discount & access